研究者業績
  1. 研究者検索結果一覧
  2. 嘉田 晃子

嘉田 晃子

Akiko Kada

基本情報

所属
藤田医科大学 橋渡し研究シーズ探索センター  准教授
学位
社会健康医学 修士(2002年3月 京都大学)
J-GLOBAL ID
201801012345530637
researchmap会員ID
B000306689

研究キーワード

 2

研究分野

 2

論文

 125
  • Takenao Koseki, Masashi Kondo, Hidetsugu Fujigaki, Kayoko Kikuchi, Yuko Oya, Hiroshi Kato, Tomohiro Mizuno, Naotake Tsuboi, Kenji Kawada, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi, Akiko Kada, Hikaru Yabuuchi, Kuniaki Saito, Hideyuki Saya
    JMIR research protocols 15 e87907 2026年2月12日  
    BACKGROUND: Cisplatin-induced nephrotoxicity (CIN) is a major dose-limiting adverse event that can lead to both acute and chronic kidney injury. The formation of thiol-cisplatin conjugates within renal tubular cells has been implicated as a key mechanism underlying CIN. Flopropione is an inhibitor of cysteine conjugate β-lyase 1, an enzyme that catalyzes the formation of the thiol-cisplatin conjugate, which might prevent CIN. OBJECTIVE: We designed a clinical trial to evaluate the safety of flopropione in patients receiving cisplatin-based chemotherapy and explore its efficacy in preventing CIN. METHODS: This is a phase 1 and 2a, single-center, randomized, open-label trial conducted in patients undergoing cisplatin therapy. Participants are randomized in a 5:2 ratio per cohort to receive either flopropione or no treatment. On the day of cisplatin administration, the flopropione group receives oral flopropione twice daily (80 mg in cohort 1, 160 mg in cohort 2, and 240 mg in cohort 3). On the following day, all cohorts receive 3 doses of 80 mg of oral flopropione. A step-up dose escalation design is adopted, progressing from cohort 1 to 3 after confirming safety at each level. The primary end point is the safety of flopropione use in combination with cisplatin; the secondary end points include changes in the levels of urinary biomarkers of nephrotoxicity such as neutrophil gelatinase-associated lipocalin, liver-type fatty acid-binding protein, and kidney injury molecule-1. Blood and urine samples are collected within 48 hours before cisplatin administration and at 24 hours, 48 hours, and 1 week after its initiation for safety and efficacy assessments. RESULTS: The first participant was registered in July 2024. As of January 2026, participant registration is ongoing. The final participant will complete the study by March 2026. Publication of results is expected by March 2027. CONCLUSIONS: This study is expected to contribute to advances in preventive strategies for CIN by providing evidence that inhibition of cysteine conjugate β-lyase 1 by flopropione may attenuate CIN. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs041220021; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041220021. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/87907.
  • Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M Saito, Kei Fukuhara, Masahiro Sekimizu
    Cancer science 2025年12月28日  
    Clinical development of crizotinib in children with ALK-positive anaplastic large cell lymphoma (ALCL) was advanced in the US but not in Japan. The objectives of phase 1 part of a clinical study in Japan were to assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of crizotinib in children with relapsed/refractory (R/R) ALK-positive ALCL or neuroblastoma (NB). Two dose levels (165 and 280 mg/m2 twice daily (BID)) were planned to be evaluated. The aim of phase 2 part of the study was to assess the antitumor activity of crizotinib at the RP2D in children with R/R ALK-positive ALCL. Seven patients were eligible for phase 1 part, 5 with ALCL and 2 with NB. All 7 patients received crizotinib at a starting dose of 165 mg/m2 BID, with 1 dose-limiting toxicity observed (grade 3 gamma-glutamyltransferase increased). The most common grade 3 or 4 adverse event was neutropenia (71%). The steady-state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. Considering the risk of a greater incidence of severe neutropenia, we decided that the 165 mg/m2 BID be the RP2D without evaluation at 280 mg/m2 BID. A total of 11 patients with ALK-positive ALCL were enrolled in the phase 2 part. The objective response rate was 72.7% (90% CI, 43.6%-92.1%). One patient permanently discontinued crizotinib due to disease progression. Crizotinib at 165 mg/m2 BID was well tolerated and showed favorable antitumor activity in children with R/R ALK-positive ALCL. Trial Registration: UMIN-CTR: UMIN000028075.
  • Yuki Nakagawa, Shigeo Tanabe, Hikaru Kondo, Koki Tan, Soichiro Koyama, Shin Kitamura, Akiko Kada, Takuma Ishihara, Takuaki Yamamoto, Junya Denda, Hideaki Kimata, Taisuke Yamanaka, Ryosuke Umezawa, Yoshinobu Nakahashi, Yohei Otaka
    JMIR Formative Research 9 e71265-e71265 2025年10月16日  
    Abstract Background Various digital biomarkers have been explored to detect cognitive impairment in community-dwelling older individuals, among which electricity consumption (EC) data obtained from smart meters are novel and promising because they pose no burden to the individuals. Objective The study aimed to explore the potential of EC as a digital biomarker to screen older individuals with cognitive impairment living alone. Methods We recruited 40 older individuals living alone and recorded their 1-year daily household EC data. We used the Japanese version of the Montreal Cognitive Assessment to categorize participants into 2 groups: those with and without cognitive impairment. As the pattern of daily household EC is different between lower and higher temperature ranges because of the use of heating and cooling equipment, we divided the daily household EC into 3 temperature ranges. Using a linear mixed model, we evaluated the association between daily household EC, daily outside temperature, and the groups. Results After excluding 12 participants, they were categorized into 2 groups: those with (10/28, 36%) and without cognitive impairment (18/28, 64%). The daily household EC data consisting of 9391 points showed two characteristics: (1) daily household EC was significantly lower in the group with cognitive impairment than in the group without cognitive impairment in the high temperature range (2.158 kWh at 25 °C, P=.02; 3.712 kWh at 30 °C, P<.001). The increase in EC with rising temperature from 25 °C to 30 °C was less in the group with cognitive impairment (2.387 kWh, P<.001) than in the group without cognitive impairment (3.940 kWh, P<.001); and (2) a tendency for lower daily household EC in the group with cognitive impairment was observed in the moderate temperature range (1.795 kWh at 15 °C, P=.06; 1.582 kWh at 20 °C, P=.08). Conclusions The group with cognitive impairment may use less cooling equipment in the high temperature range and fewer home appliances in the moderate temperature range. Daily household EC might be useful in screening cognitive impairment in older individuals living alone.
  • Motohiro Kato, Yasuhiro Okamoto, Toshihiko Imamura, Akiko Kada, Akiko M Saito, Yuka Iijima-Yamashita, Takao Deguchi, Kentaro Ohki, Takashi Fukushima, Kenichi Anami, Masashi Sanada, Tomohiko Taki, Yoshiko Hashii, Takeshi Inukai, Nobutaka Kiyokawa, Yoshiyuki Kosaka, Nao Yoshida, Yuki Yuza, Masakatsu Yanagimachi, Kenichiro Watanabe, Atsushi Sato, Chihaya Imai, Takashi Taga, Souichi Adachi, Keizo Horibe, Atsushi Manabe, Katsuyoshi Koh
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology JCO2400811 2024年11月12日  
    PURPOSE: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS: Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION: The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.
  • Hiroaki Goto, Akiko Kada, Chitose Ogawa, Ritsuo Nishiuchi, Junko Yamanaka, Akihiro Iguchi, Masanori Nishi, Kimiyoshi Sakaguchi, Tadashi Kumamoto, Shinji Mochizuki, Hideaki Ueki, Yoshiyuki Kosaka, Akiko M. Saito, Hidemi Toyoda
    International Journal of Hematology 120(5) 631-638 2024年8月27日  
もっとみる

MISC

 48

講演・口頭発表等

 1

共同研究・競争的資金等の研究課題

 6
もっとみる
一覧へ戻る